Athira Pharma Inc (ATHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Athira Pharma Inc (ATHA) has a cash flow conversion efficiency ratio of -0.698x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.40 Million) by net assets ($27.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Athira Pharma Inc market capitalisation for the company's overall valuation and market capitalisation.
Athira Pharma Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Athira Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Athira Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Athira Pharma Inc ranked by their cash flow conversion efficiency. See Athira Pharma Inc debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Embrace Change Acquisition Corp Ordinary Shares
NASDAQ:EMCG
|
0.015x |
|
Kwang Myung El
KO:017040
|
0.147x |
|
PM Thoresen Asia Holdings PCL
BK:PMTA
|
-0.084x |
|
United Homes Group Inc.
NASDAQ:UHG
|
0.021x |
|
Systech Bhd
KLSE:0050
|
1.187x |
|
Worth Peripherals Limited
NSE:WORTH
|
0.067x |
|
KLX Energy Services Holdings Inc
NASDAQ:KLXE
|
-0.224x |
|
Perusahaan Sadur Timah Malaysia Perstima Bhd
KLSE:5436
|
0.069x |
Annual Cash Flow Conversion Efficiency for Athira Pharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Athira Pharma Inc from 2018 to 2025. View Athira Pharma Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.79 Million | $-45.73 Million | -1.646x | +24.06% |
| 2024-12-31 | $44.84 Million | $-97.17 Million | -2.167x | -180.01% |
| 2023-12-31 | $130.19 Million | $-100.75 Million | -0.774x | -151.11% |
| 2022-12-31 | $235.14 Million | $-72.47 Million | -0.308x | -129.61% |
| 2021-12-31 | $321.08 Million | $-43.10 Million | -0.134x | -52.68% |
| 2020-12-31 | $274.28 Million | $-24.11 Million | -0.088x | -146.70% |
| 2019-12-31 | $-19.72 Million | $-3.71 Million | 0.188x | -37.48% |
| 2018-12-31 | $-14.89 Million | $-4.48 Million | 0.301x | -- |
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more